To modify the current standard of care for glioblastoma by replacing radiation and chemotherapy with targeted small molecule therapies that prolong survival and increase quality of life.
Glioblastoma (also known as Glioblastoma multiforme or GBM) is the most aggressive type of tumor that arises in the brain. It is one of the most lethal forms of brain cancer. The current standard of care (consisting of surgery, radiation and chemotherapy) is ineffective, and the median survival of a person diagnosed with glioblastoma is about 15 months; without treatment, it is a paltry 3-6 months. Although radiation and chemotherapy prolong life, they greatly reduce quality of life-so much so, in fact, that some patients opt out of treatment.
The purpose of Glioblastoma Foundation is to transform the standard of care for glioblastoma by supporting the development of drug therapies for glioblastoma. Researchers have found that each glioblastoma is different, and as such a targeted approach to therapy may be necessary. Glioblastoma Foundation focuses on supporting the development of targeted therapies, those based on the molecular features of each tumor. It is likely that no one therapy will be enough to beat glioblastoma. Multiple drugs will inevitably be needed to block the many molecular signaling pathways present in glioblastoma, thereby disabling the cellular machinery that allows tumors to recur.
The research we support will transform glioblastoma therapy and prolong the lives of glioblastoma patients. We need your help. Please join us on the journey to improve the prognosis and quality of life of patients diagnosed with glioblastoma.
Write a review